Cell-type-specific role of cullin 3 in adipocytes and hepatocytes: metabolic implications of neddylation inhibition

Keywords

Neddylation / Cullin 3 / Obesity / Fatty liver disease / NRF2

Ethical statements

Not applicable.

Author contributions

The authors confirm contributions to the paper as follows: study conception, manuscript revision and supervision: Yu B, Qin T; draft manuscript preparation, figure creation: Yuan Z, Wang Z; critical revision and expert input: Yuan Z, Wang Z; funding acquisition Yu B, Yuan Z. All authors reviewed the results and approved the final version of the manuscript.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Acknowledgments

This study was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (Grant No. 2023ZD0507700), National Natural Science Foundation of China (Grant No. 82304587), Natural Science Foundation of Henan Province (Grant Nos 242301420005 and 252300421243), Young Elite Scientists Sponsorship Program by Henan Association for Science and Technology (Grant No. 2025HYTP076), Key Research Project for Basic Research in Henan Province Universities (Grant No. 25ZX001), Scientific Research Innovation Capability Support Project for Young Faculty (Grant No. SRICSPYF-BS2025078), China Postdoctoral Science Foundation (Grant No. 2024M750816), State Key Laboratory of Metabolic Dysregulation and Prevention and Treatment of Esophageal Cancer (Grant No. 2025SGAQZ-MS-01) and Henan Province Clinical Medical Scientists Training Program (Grant No. HNCMS202410).

Conflict of interest

The authors declare no conflict of interest.

References

[1] Zhang S, Yu Q, Li Z, Zhao Y, Sun Y. 2024. Protein neddylation and its role in health and diseases. Signal Transduction and Targeted Therapy 9:85

[2] Lu X, Kong X, Wu H, Hao J, Li S, et al. 2023. UBE2M-mediated neddyla-tion of TRIM21 regulates obesity-induced inflammation and metabolic disorders. Cell Metabolism 35:1390-1405.e8

[3] Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, et al. 2009. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732-736

[4] Serrano-Maciá M, Simón J, González-Rellan MJ, Azkargorta M, Goikoetxea-Usandizaga N, et al. 2021. Neddylation inhibition amelio-rates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism 53:101275

[5] Park HS, Ju UI, Park JW, Song JY, Shin DH, et al. 2016. PPARγ neddyla-tion essential for adipogenesis is a potential target for treating obesity. Cell Death & Differentiation 23:1296-1311

[6] Gonzalez-Rellan MJ, Fernández U, Parracho T, Novoa E, Fondevila MF, et al. 2023. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism. Cell Metabolism 35:1630-1645.e5

[7] Ren H, Luan Z, Zhang R, Zhang H, Bian C. 2024. A novel approach to explore metabolic diseases: neddylation. Pharmacological Research 210:107532

[8] Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, et al. 2022. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. Journal of Hematology & Oncology 15:56

[9] Gu L, Du Y, Nazmul Hasan M, Clayton YD, Li T. 2025. Adipose cullin 3 mediates the antiobesity effect of pan neddylation inhibitors. Proceed-ings of the National Academy of Sciences of the United States of America 122:e2515947122

[10] Gu L, Du Y, Chen J, Hasan MN, Clayton YD, et al. 2024. Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 121:e2320934121

[11] Chen C, Gu L, Matye DJ, Clayton YD, Hasan MN, et al. 2022. Cullin neddylation inhibitor attenuates hyperglycemia by enhancing hepatic insulin signaling through insulin receptor substrate stabilization. Proceedings of the National Academy of Sciences of the United States of America 119:e2111737119

[12] Ju UI, Jeong DW, Seo J, Park JB, Park JW, et al. 2020. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment. Cell Death & Disease 11:283

[13] Ni HM, Woolbright BL, Williams J, Copple B, Cui W, et al. 2014. Nrf 2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. Journal of Hepatology 61:617-625

[14] He Z, Yuan Z, Yang F, Zhang J, Zhao W, et al. 2024. A comprehensive review on DCN1 protein, inhibitors and their therapeutic applications. International Journal of Biological Macromolecules 277:134541

[15] He ZX, Gao G, Qiao H, Dong GJ, Dan Z, et al. 2024. Discovery of 1,2,4-triazole-3-thione derivatives as potent and selective DCN1 inhibitors for pathological cardiac fibrosis and remodeling. Journal of Medicinal Chemistry 67:18699-18723